jRCT2080222529已完成1 期
Phase I Study of RO5541077 in Patients with B cell Non-Hodgkin s Lymphoma
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Open-label, Dose-escalation study
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 20age old over 至 74age old under（—）
- 性别
- All
入选标准
- •Performance status (PS) of 0 or 1
- •Relapsed or refractory B cell NHL for which there is no prior standard treatment
- •Sufficient major organ function
排除标准
- •Pregnant or lactating women or women who have tested positive on a pregnancy test
- •Current or previous history of clinically significant disease
- •Current or previous history of central nervous system lymphoma
- •Invasion to the CNS of the primary disease
结局指标
主要结局
-
safety pharmacokinetics Assessment and observations
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Phase I Study of RO5541077 in Patients with B cell Non-Hodgkin s LymphomaB cell Non-Hodgkin s LymphomaJPRN-jRCT2080222529Chugai Pharmaceutical Co., Ltd.7
已完成
1 期
A PHASE I STUDY OF RO7082859 IN PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMAjRCT2080225077Chugai Pharmaceutical Co., Ltd.12
已完成
1 期
A PHASE I STUDY OF RO7082859 IN PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMAon Hodgkin's LymphomaJPRN-jRCT2080225077Chugai Pharmaceutical Co., Ltd.12
进行中（未招募）
1 期
A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaCML and Ph+ALLMedDRA version: 8.1 Level: LLT Classification code 10000845 Term: Acute lymphoblastic leukemiaEUCTR2006-004535-30-DKMerck & Co., Inc.3
进行中（未招募）
不适用
A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaCML and Ph+ALLMedDRA version: 8.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaMedDRA version: 9.1Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaEUCTR2006-004535-30-DEMerck & Co., Inc.272